BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,168.00
- Market cap
- ₹15,420 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 86.8×Sector 48.6×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Partnership
AstraZeneca Pharma India signed a Letter of Intent with Strand Life Sciences to explore healthcare collaboration in India. No specific project value or new entity is involved.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India may receive a revised Bengaluru civic demand for improvement charges. Charges are likely capped at Rs.70.8 million plus interest, and Rs.156.1 million is already provided.
- Value
- ₹7.08 Cr
AstraZeneca Pharma India Results Update
AstraZeneca Pharma India reported 30% growth in Q2 results, with three new regulatory approvals. It also announced MoUs with two state governments.
AstraZeneca Pharma India Q2 FY27 Results: Net Profit ₹62.3 Cr, Up 14.9% YoY
AstraZeneca Pharma India Ltd reported revenue from operations of ₹729.1 Cr (+30.4% YoY) and net profit of ₹62.3 Cr (+14.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹62.3 Cr · +14.9% YoY
AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
Other annual general meeting announcements
All →Khazanchi Jewellers Annual General Meeting
Khazanchi Jewellers' EGM on November 17, 2026 approved Ms. Simran Lodha's appointment as Independent Director for three years. The resolution was a special resolution passed via e-voting.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma seeks postal ballot approval for revised remuneration of its whole-time director and managing director. E-voting closes 17 December 2026.
Prataap Snacks Annual General Meeting
Prataap Snacks issued a postal ballot notice seeking approval to appoint Jitendra Nayyar and Sumit Sharma as directors and to reclassify some promoter group members as public. Voting ends December 18, 2026.
Sayaji Hotels Annual General Meeting
Sayaji Hotels filed a postal ballot notice seeking shareholder approval to appoint two non-executive non-independent directors. E-voting runs from 18 November to 18 December 2026.
Bliss GVS Pharma Annual General Meeting
Bliss GVS Pharma's postal ballot sought approval to appoint three Non-Executive Non-Independent Directors. The voting results show all three resolutions passed with majority approval.
Coreintegra Consulting Services Annual General Meeting
Coreintegra seeks postal ballot approval to vary IPO fund objects and utilise Rs 15.15 Crore of unutilised proceeds. E-voting runs until 17 December 2026.
- Value
- ₹15.15 Cr
- Execution
- E-voting from 18 November 2026 (09:00 a.m.) to 17 December 2026 (05:00 p.m.)